Gastric Retention and Controlled Release Delivery System
The present invention provice a device (FIG. 3 ) for providing communication through power lines (FIG. 2 ) comprised of multiple conductors by transmitting the data signals through a plurality of the conductors. One embodiment of the present invention comprises a transmit circuit communicatively coupled to a first conductor for applying the first voltage representing the data to the first energized conductor; the transmit circuit communicatively coupled to a second conductor for applying the second voltage representing the data to the second energized conductor; wherein the second voltage signal is opposite in polarity of the first voltage.
1 . A pharmaceutical composition comprising:
(a) an active agent;
(b) a delivery agent compound;
(c) at least one of a swellable polymer, or a mucoadhesive; and
d) a release controlling polymer;
wherein the pharmaceutical composition comprises two layers, wherein the first layer consists essentially of a swellable polymer, and the second layer comprises an active agent and a delivery agent compound.
2 . (canceled)
3 . The pharmaceutical composition of claim 1 wherein the swellable polymer is selected from a crosslinked poly(acrylic acid), a poly(alkylene oxide), a poly(vinyl alcohol), a poly(vinyl pyrrolidone), a polyurethane hydrogel, a maleic anhydride polymer, a cellulose polymer, a polysaccharide, astarch, and a starch based polymer.
4 . The pharmaceutical composition of claim 1 wherein the swellable polymer is a poly(alkylene oxide).
5 . The pharmaceutical composition of claim 4 , wherein the poly(alkylene oxide) is a polymer contains at least one of ethylene oxide or propylene oxide as a monomer unit.
6 . The pharmaceutical composition of claim 1 wherein the swellable polymer is a poly(ethylene oxide) having a molecular weight in excess of 500,000 daltons.
7 . The pharmaceutical composition of claim 1 wherein the swellable polymer is a poly(ethylene oxide) having a molecular weight in excess of 7,000,000 daltons.
8 . The pharmaceutical composition of claim 1 wherein the swellable polymer is a polyethylene oxide having an average molecular weight of about 7,000,000.
9 . The pharmaceutical composition of claim 1 wherein the release controlling polymer is selected from a poly(ethylene oxide), a poly(acrylic acid), a poly(acrylate), a polyvinyl alcohol, an alginate, a chitosan, a polyvinylpyrrolidone, a cellulose polymer and a polysaccharide.
10 . The pharmaceutical composition of claim 1 wherein the release controlling polymer is a poly(ethylene oxide) having a molecular weight of about 300,000 dattons or less.
11 . The pharmaceutical composition of claim 1 wherein the release controlling polymer is a poly(ethylene oxide) having a molecular weight of about 200,000 dattons or less.
12 . The pharmaceutical composition of claim 1 wherein the release controlling polymer is a polyethylene oxide having an average molecular weight of about 200,000.
13 . The pharmaceutical composition of claim 1 wherein the release controlling polymer is a poly(acrylic acid) or a poly(acrylate).
14 - 15 . (canceled)
16 . The pharmaceutical composition of claim 1 wherein the mucoadhesive is selected from a polyacrylic acid or polyacrylate optionally cross-linked with allyl sucrose, allyl ethers of sucrose, allylpentaerythritol, pentaerythritol or divinyl glycol; a carboxylvinyl polymer; a polyvinyl pyrrolidone (PVP); polyvinyl alcohol; sodium carboxymethylcellulose (CMC); a dextran polymer; a copolymer of polymethyl vinyl ether and maleic anhydride; hydroxymethylcellulose; methylcellulose; a tragacanth; an alginic acid; gelatin; gum arabic; and a polysaccharide optionally interrupted with a β-(1-4)-linked D-glucosamine unit and/or a N-acetyl-D-glucosamine unit, and mixtures thereof.
17 . The pharmaceutical composition of claim 16 , wherein the mucoadhesive is selected from chitosan or a carboxyvinyl polymer.
18 . The pharmaceutical composition of claim 17 , wherein the mucoadhesive is a high-molecular-weight homopolymer of acrylic acid crosslinked with allyl sucrose or allyl pentaerythritol having a viscosity of 29,400-39,400 cP at 0.5 wt % at pH 7.5.
19 . The pharmaceutical composition of claim 1 wherein the composition contains both a swellable polymer and a release controlling polymer.
20 . The pharmaceutical composition of claim 1 wherein the active agent is absorption lasts up to 1.5 hours after oral administration to a mammal.
21 . The pharmaceutical composition of claim 1 wherein the active agent is absorption lasts up to 6.0 hours after oral administration to a mammal.
22 . The pharmaceutical composition of claim 1 wherein the composition increases in volume by at least about 10-15% within about 30 minutes of oral administration by a mammal.
23 - 41 . (canceled)